A muscle relaxant could be beneficial to patients with alcohol-induced liver disease (ALD) in reducing alcohol consumption and overall measures of liver function and harm, according to a study presented at the 50th International Liver Congress in Vienna, Austria.
In this preliminary study, researchers aimed to measure the efficacy and tolerability of baclofen in maintaining abstinence from alcohol in patients with ALD and any impact on standard measures of liver damage. The results indicated that baclofen helped these patients reduce their alcohol consumption and improve overall indicators of liver function and lowering alcohol dependence.
Based on these promising findings, a randomized controlled trial is needed to confirm these benefits of baclofen in patients with ALD. Baclofen is a muscle relaxant currently indicated for the treatment of spasticity associated with multiple sclerosis (MS) and spinal cord injury or disease.
For more information visit EASL.eu.